Vaccination Clinical Trial
Official title:
A Study to Evaluate the Safety, Reactogenicity, and Acceptability of a Placebo Microneedle Patch in Healthy Infants and Young Children
NCT number | NCT03207763 |
Other study ID # | IRB00096635 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 11, 2017 |
Est. completion date | May 15, 2019 |
Verified date | October 2020 |
Source | Emory University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Microneedles can be prepared as a low-cost patch that is simple for patients to apply for vaccine delivery targeting the many antigen-presenting cells present in the skin. Data regarding the safety, reactogenicity, tolerability, and acceptability of a microneedle patch in children are lacking. The goal of this study is to evaluate the safety, reactogenicity, and acceptability of placement of a placebo microneedle patch to the skin of children.
Status | Completed |
Enrollment | 33 |
Est. completion date | May 15, 2019 |
Est. primary completion date | May 15, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 6 Weeks to 24 Months |
Eligibility | Inclusion Criteria: - Legally Authorized Representative (LAR) provides written informed consent prior to any study procedures being performed. - Subject is between the ages of 6 weeks and 24 months, inclusive, on the day of signing informed consent. - Subject is in good health as determined by vital signs, medical history, and a targeted physical examination. - LAR is able to understand and comply with required study procedures. Exclusion Criteria: - Subject has an acute illness with fever (temperature >100.4 °F) within 72 hours prior to enrollment. - Subject has a known chronic medical problem. - Subject has known immunosuppression due to underlying illness or treatment, including (but not limited to): Human Immunodeficiency Virus (or birth to a HIV-positive mother), hepatitis B or C; organ transplant; active cancer or any history of hematologic cancer; receipt of chemotherapy or radiation therapy; congenital immunodeficiency, anatomical or functional asplenia. - Subject has used long-term* high-dose** oral or parenteral glucocorticoids, or high-dose inhaled steroids.*** * Long term is defined as taken for 2 weeks or more in total at any time during the past 2 months. ** High dose defined as prednisone = 20 mg total daily dose, or equivalent dose of other glucocorticoids. *** High dose defined as >800 mcg/day of beclomethasone dipropionate or equivalent. - Subject has a history of an underlying skin condition (e.g., eczema, atopic dermatitis) or an open lesion (e.g., laceration, abrasion), scar, or rash in the areas of the planned microneedle patch administration which will interfere with the assessment of reactogenicity. - Subject or family members have a history of keloid formation. - Subject has any condition that, in the opinion of the investigator, may put the subject at increased risk of harm, may cause the subject to be unable to meet the requirements or might otherwise interfere with evaluations required by the study. - Subject has received any experimental products within 30 days before study entry or plan to receive experimental products at any time during the study. - Subject has received a vaccine within 7 days of enrollment or plans to receive a vaccine within 7 days after enrollment. - Subject has previously received immunoglobulin or blood products. |
Country | Name | City | State |
---|---|---|---|
United States | Emory Children's Center | Atlanta | Georgia |
Lead Sponsor | Collaborator |
---|---|
Emory University | Micron Biomedical, Inc |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Placebo Microneedle Patch-related Serious Adverse Events (SAE). | To evaluate safety following application of the patch topically, microneedle patch-related serious adverse events were recorded. Information collected included event description, date of onset, severity and date of resolution/stabilization of the event. Severity and relationship to study product was assessed by the Investigator or sub-investigator. | Day 1 through the Final Study Visit (Day 27 - 38) | |
Primary | Number of Participants With Grade 3 Placebo Microneedle Patch-related Solicited Adverse Events (AE). | The occurrence of Grade 3 solicited adverse events related to the placebo microneedle patch was recorded. Solicited adverse events were irritability (fussiness), lethargy (drowsiness), decreased appetite, vomiting, and fever. The severity of these adverse events was graded on a scale from 0 to 3 where 0 = not present and 3 = significant, preventing daily activity or a fever of >102.1 degrees Fahrenheit (F). | Up to Day 8 for Patch 1, Day 8 to Day 15 if received Patches 2 and 3 | |
Primary | Number of Participants With Solicited Application Site Reactogenicity Events. | The occurrence of solicited reactogenicity events at the application site was recorded. The solicited reactogenicity events are reactions that are common or expected to occur with application of a microneedle patch and include induration/swelling, erythema, ecchymosis, itching, pain, and tenderness. The Legally Authorized Representatives (LARs) of participants were provided with a memory aid, thermometer and ruler to record the presence of solicited symptoms and oral temperature. Reactogenicity event details were collected via review of the subject's memory aid and by interview with the subject LAR. Reactogenicity events were graded on a scale from 0 (not present) to 3 (significant or severe). | Up to Day 8 for Patch 1, Day 8 to Day 15 if received Patches 2 and 3 | |
Secondary | Number of Participants With Grade 3 Placebo Microneedle Patch-related Unsolicited Adverse Events | Grade 3, patch-related unsolicited adverse events (AEs) were recorded. An adverse event is graded as Grade 3 if the event is significant or prevents daily activity. | Day 1 through the Final Study Visit (Day 27 - 38) | |
Secondary | Number of New-onset Medical Conditions (NOMC) | The number of new-onset medical conditions (NOMC) were recorded. NOMC were tabulated by overall and treatment related events. | Day 1 through the Final Study Visit (Day 27 - 38). | |
Secondary | Acceptability of Vaccination Methods | LARs were asked to state their preference for different methods of vaccine delivery, assuming that a vaccine patch were to be available in the next two years. LARs reported their preference for their child receiving 1) a vaccine by shot or nasal spray given by a healthcare worker, 2) a vaccine patch given by a healthcare worker, 3) a vaccine patch given by the LAR but monitored by a healthcare worker, or 4) a vaccine patch given by the LAR at home. LARs rated their preference on a scale from 0 (definitely not) to 10 (definitely so). | Final Visit (Day 27 - 38) | |
Secondary | Overall Experience | LARs were asked to report their overall experience with the study so far at each study visit related to Patch 1. Experiences were rated on a scale from 1 to 5 where 1 = very negative and 5 = very positive. | Day 1, Day 2, Day 8, Final Visit (Day 27-38) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03284515 -
Vaccination In Pregnancy Gene Signature: VIP Signature Study
|
||
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Recruiting |
NCT05996549 -
Cost-effectiveness of the Influenza Vaccination
|
Phase 4 | |
Completed |
NCT04323137 -
Encouraging Flu Vaccination Among High-Risk Patients Identified by ML
|
N/A | |
Completed |
NCT01224301 -
School Influenza Vaccine vs Standard of Care With Nested Trial of 2 Parent Notification Intensities
|
N/A | |
Completed |
NCT00169858 -
Long Term Immunogenicity Study of Engerix-B Vaccine in 10 Year Old Children and the Effect of Booster Injections
|
Phase 4 | |
Completed |
NCT05509283 -
Nudging Flu Vaccination in Patients at Moderately High Risk for Flu and Flu-related Complications
|
N/A | |
Completed |
NCT02907580 -
Influenza Vaccine Attitudes, Intent, and Receipt: Pediatric
|
N/A | |
Recruiting |
NCT06160999 -
Improving Uptake of Pediatric Vaccines Through Religious Conferences and Vaccines-in-a-van in Aceh, Indonesia
|
N/A | |
Recruiting |
NCT03875703 -
Post-Vaccination Biological Collection
|
||
Completed |
NCT03287830 -
Flu2Text: Text Message Reminders for 2nd Dose of Influenza Vaccine
|
N/A | |
Completed |
NCT02907645 -
Influenza Vaccine Randomized Educational Trial: Adult
|
N/A | |
Completed |
NCT03220555 -
Efficacy of the Buzzy® Device on the Prevention of Health Care Induced Pediatric Pain in a Vaccination Center
|
N/A | |
Withdrawn |
NCT05023512 -
Understanding Public Attitudes Towards the COVID-19 Vaccination
|
N/A | |
Recruiting |
NCT02937428 -
To Look or Not to Look at the Needle During Vaccination
|
Phase 3 | |
Completed |
NCT00813319 -
Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females
|
Phase 3 | |
Completed |
NCT03104790 -
Assessment of Viral Shedding in Children Previously in Receipt of Multiple Doses of Live Attenuated Influenza Vaccine (LAIV) Compared to Influenza Vaccine-naïve Controls
|
Phase 4 | |
Completed |
NCT04780867 -
Psychological and Lifestyle Factors on Health Outcomes
|
N/A | |
Completed |
NCT03239795 -
Promoting Influenza Vaccination In General Practice Waiting Rooms
|
N/A |